Cargando…
A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases
Treatment effects are often anticipated to vary across groups of patients with different baseline risk. The Predictive Approaches to Treatment Effect Heterogeneity (PATH) statement focused on baseline risk as a robust predictor of treatment effect and provided guidance on risk-based assessment of tr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060247/ https://www.ncbi.nlm.nih.gov/pubmed/36991144 http://dx.doi.org/10.1038/s41746-023-00794-y |
_version_ | 1785017059601547264 |
---|---|
author | Rekkas, Alexandros van Klaveren, David Ryan, Patrick B. Steyerberg, Ewout W. Kent, David M. Rijnbeek, Peter R. |
author_facet | Rekkas, Alexandros van Klaveren, David Ryan, Patrick B. Steyerberg, Ewout W. Kent, David M. Rijnbeek, Peter R. |
author_sort | Rekkas, Alexandros |
collection | PubMed |
description | Treatment effects are often anticipated to vary across groups of patients with different baseline risk. The Predictive Approaches to Treatment Effect Heterogeneity (PATH) statement focused on baseline risk as a robust predictor of treatment effect and provided guidance on risk-based assessment of treatment effect heterogeneity in a randomized controlled trial. The aim of this study is to extend this approach to the observational setting using a standardized scalable framework. The proposed framework consists of five steps: (1) definition of the research aim, i.e., the population, the treatment, the comparator and the outcome(s) of interest; (2) identification of relevant databases; (3) development of a prediction model for the outcome(s) of interest; (4) estimation of relative and absolute treatment effect within strata of predicted risk, after adjusting for observed confounding; (5) presentation of the results. We demonstrate our framework by evaluating heterogeneity of the effect of thiazide or thiazide-like diuretics versus angiotensin-converting enzyme inhibitors on three efficacy and nine safety outcomes across three observational databases. We provide a publicly available R software package for applying this framework to any database mapped to the Observational Medical Outcomes Partnership Common Data Model. In our demonstration, patients at low risk of acute myocardial infarction receive negligible absolute benefits for all three efficacy outcomes, though they are more pronounced in the highest risk group, especially for acute myocardial infarction. Our framework allows for the evaluation of differential treatment effects across risk strata, which offers the opportunity to consider the benefit-harm trade-off between alternative treatments. |
format | Online Article Text |
id | pubmed-10060247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100602472023-03-31 A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases Rekkas, Alexandros van Klaveren, David Ryan, Patrick B. Steyerberg, Ewout W. Kent, David M. Rijnbeek, Peter R. NPJ Digit Med Article Treatment effects are often anticipated to vary across groups of patients with different baseline risk. The Predictive Approaches to Treatment Effect Heterogeneity (PATH) statement focused on baseline risk as a robust predictor of treatment effect and provided guidance on risk-based assessment of treatment effect heterogeneity in a randomized controlled trial. The aim of this study is to extend this approach to the observational setting using a standardized scalable framework. The proposed framework consists of five steps: (1) definition of the research aim, i.e., the population, the treatment, the comparator and the outcome(s) of interest; (2) identification of relevant databases; (3) development of a prediction model for the outcome(s) of interest; (4) estimation of relative and absolute treatment effect within strata of predicted risk, after adjusting for observed confounding; (5) presentation of the results. We demonstrate our framework by evaluating heterogeneity of the effect of thiazide or thiazide-like diuretics versus angiotensin-converting enzyme inhibitors on three efficacy and nine safety outcomes across three observational databases. We provide a publicly available R software package for applying this framework to any database mapped to the Observational Medical Outcomes Partnership Common Data Model. In our demonstration, patients at low risk of acute myocardial infarction receive negligible absolute benefits for all three efficacy outcomes, though they are more pronounced in the highest risk group, especially for acute myocardial infarction. Our framework allows for the evaluation of differential treatment effects across risk strata, which offers the opportunity to consider the benefit-harm trade-off between alternative treatments. Nature Publishing Group UK 2023-03-30 /pmc/articles/PMC10060247/ /pubmed/36991144 http://dx.doi.org/10.1038/s41746-023-00794-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Rekkas, Alexandros van Klaveren, David Ryan, Patrick B. Steyerberg, Ewout W. Kent, David M. Rijnbeek, Peter R. A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases |
title | A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases |
title_full | A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases |
title_fullStr | A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases |
title_full_unstemmed | A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases |
title_short | A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases |
title_sort | standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060247/ https://www.ncbi.nlm.nih.gov/pubmed/36991144 http://dx.doi.org/10.1038/s41746-023-00794-y |
work_keys_str_mv | AT rekkasalexandros astandardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT vanklaverendavid astandardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT ryanpatrickb astandardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT steyerbergewoutw astandardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT kentdavidm astandardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT rijnbeekpeterr astandardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT rekkasalexandros standardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT vanklaverendavid standardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT ryanpatrickb standardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT steyerbergewoutw standardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT kentdavidm standardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases AT rijnbeekpeterr standardizedframeworkforriskbasedassessmentoftreatmenteffectheterogeneityinobservationalhealthcaredatabases |